RAS proteins have long been an elusive cancer drug target. New preclinical research in nature from KenOliveLab shows the potential of an entire new class of experimental drugs that could treat almost all forms of pancreatic cancer - and maybe even more.
cuimc.columbia.edu/news/opening-n…

Out NOW in Cancer Discovery!!! Don’t miss this new paper evaluating RMC-6246 in RAS-driven cancers that was just covered during #AACR24 . The data is so exciting and Ras-nerds will love it!

I think we all need to take note of the fact that my dear friend Dr. Mallika Singh, from RevMed, was senior or co-senior author on TWO nature papers and an Cancer Discovery paper in the space of 24 hours. Just epic. World class scientist. So happy for her and all who contributed.

The last of a triumvirate of papers on RevMed pan-RAS-GTP inhibitors posted today Cancer Discovery. RMC-6236 is related to RMC-7977, the agent we published on yesterday. It is in Phase 1/2 clinical trials and headed to Phase 3 in #pdac . aacrjournals.org/cancerdiscover…